Rubicon Research Limited (BOM:544578)

Market Cap	165.67B
Revenue (ttm)	17.62B +106.3%
Net Income	2.47B +171.1%
EPS	15.31 +159.1%
Shares Out	n/a
PE Ratio	67.15
Forward PE	50.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,813
Open	982.50
Previous Close	965.80
Day's Range	970.25 - 1,020.00
52-Week Range	571.00 - 1,020.00
Beta	n/a
Analysts	Strong Buy
Price Target	1,175.00 (-9.36%)
Earnings Date	May 29, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 903
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544578

Financial Performance

In fiscal year 2026, Rubicon Research's revenue was 17.62 billion, an increase of 37.17% compared to the previous year's 12.84 billion. Earnings were 2.47 billion, an increase of 83.63%.